{"entity":{"id":"plx-66140","kind":"drug","name":"PLX-66140","aka":[],"tldr":"PLX-66140 is an experimental oral molecular glue degrader from Plexium, in preclinical development for ER-positive/HER2-negative breast cancer and CCNE1-amplified tumours.","summary":"PLX-66140 is an oral molecular glue degrader (cereblon) from Plexium. A cereblon-based molecular glue that degrades CDK2, aimed at tumours driven by cyclin E (CCNE1) amplification or overexpression. Its furthest stage is preclinical development, for ER-positive/HER2-negative breast cancer and CCNE1-amplified tumours. No clinical trial naming it is registered on ClinicalTrials.gov. Preclinical on company pipeline chart. It has not been shown to work in people.","status":"preclinical","asOf":"2026-11-03","links":[{"label":"Plexium: plexium.com","url":"https://plexium.com/pipeline/"}],"tags":["pipeline"],"related":[],"cancers":["metastatic-cancer"],"sections":[],"technologies":[],"targets":["cdk2"],"drugs":[],"companies":["plexium"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"provenance":{"editedBy":"OnCo gap audit, class 5 (company pipeline pages and ClinicalTrials.gov v2)","editedOn":"2026-11-03"},"code":"PLX-66140","modality":"Oral molecular glue degrader (cereblon)","mechanism":"A cereblon-based molecular glue that degrades CDK2, aimed at tumours driven by cyclin E (CCNE1) amplification or overexpression.","approvals":[],"mechanismSteps":[],"toxicity":[],"access":[],"regulatoryEvents":[]},"route":"/drugs/plx-66140/","neighbours":{"cancer":[{"id":"metastatic-cancer","kind":"cancer","name":"Metastatic cancer (cancer that has spread)","route":"/cancers/metastatic-cancer/"}],"target":[{"id":"cdk2","kind":"target","name":"CDK2","route":"/targets/cdk2/"}],"company":[{"id":"plexium","kind":"company","name":"Plexium","route":"/companies/plexium/"}]}}